



February 3, 2014

Press Release

Mitsubishi Tanabe Pharma Corporation

**MT-4666 in Alzheimer's Disease
Start of Global Phase 3 Clinical Trial Program, COGNITIV AD**

Osaka, Japan, February 3, 2014—Mitsubishi Tanabe Pharma Corporation (Head office: Osaka; President & CEO: Michihiro Tsuchiya) announced today that EnVivo Pharmaceuticals, Inc. (Massachusetts, U.S.), had initiated COGNITIV AD, a global phase 3 clinical trial program for encenicline-hydrochloride (EVP-6124), in patients with Alzheimer's disease. Mitsubishi Tanabe Pharma has licensed encenicline from EnVivo and is developing it under the code MT-4666.

MT-4666 is a novel alpha-7 ($\alpha 7$) potentiator. In March 2009, Mitsubishi Tanabe Pharma acquired from EnVivo exclusive R&D, sales, and manufacturing rights for MT-4666 in Japan and other Asian countries. Mitsubishi Tanabe Pharma is moving ahead with development for patients in Japan with Alzheimer's disease. Mitsubishi Tanabe Pharma will participate in the clinical trial program, which will be led by EnVivo. Plans call for the clinical trial program to start in Japan in spring 2014.

The COGNITIV AD Phase 3 clinical trial program consists of placebo-controlled, randomized, double-blind trials that will enroll about 1,600 patients with mild to moderate Alzheimer's disease who are currently receiving stable treatment with or have been previously treated with an acetylcholinesterase inhibitor in the U.S., Europe, Japan, and other regions. Patients will be randomized to receive one of two doses of encenicline once daily or placebo. Safety and efficacy of MT-4666 will be evaluated.

Through participation in this clinical trial program, Mitsubishi Tanabe Pharma will work together with EnVivo to accelerate development of MT-4666 and to provide an effective drug for patients with Alzheimer's disease as rapidly as possible.

<Contact for Inquiries>
Corporate Communications Department
Phone: +81 6-6205-5211